REHOVOT, Israel, SINGAPORE and NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced a partnership with PATHNOVA, a Singapore-based clinical laboratory, for the Company’s breast cancer and SARS-CoV-2 diagnostic kits (the “Todos Tests”). PATHNOVA is a spin-off company of Temasek Life Sciences Laboratory (TLL), a not-for-profit research institute with a mission to harness the power of the life sciences to improve lives.
“We are excited to be running with Everyone and their complex blood tests based on synthetic intelligence TM-B1 and TM-B2 for breast cancer,” said Professor Chan Soh Ha, CEO of PATHNOVA and former CEO of TLL. “We see an early possibility of offering COVID-19 test facilities and distributing the All COVID-19 tests in Southeast Asia. We, everyone’s portfolio, have a great chance and we look forward to helping advance in Singapore and Southeast Asia.”
Under the agreements, PATHNOVA will be guilty of the progression and publicity of Everyone’s controls in Singapore, and Todos will help PATHNOVA publicize its nasopharynge cancer controls through its subsidiaries in the United States and Singapore. All will provide PATHNOVA with access to existing clinical datasets for its TM-B1 and TM-B2 breast cancer diagnoses, and PATHNOVA will largely paint with Everyone to optimize its AI-based set of rules for regulatory approval in the United States and Singapore. In contrast, All will distribute PATHNOVA’s nasopharyne cancer clinical control facilities through its subsidiaries in Israel and the United States. PATHNOVA will provide assistance as an advertising distributor of clinical verification facilities for All’s COVID-19 check offerings in Singapore and Southeast Asia, in collaboration with Everyone’s subsidiary, Singapore Medical PTE Ltd.
Commenting on the agreement, Gerald Commissiong, President and CEO of Todos Medical, said, “We are systematically building a world-class diagnostic company, and this agreement with PATHNOVA supports our goals and expands our geographic reach. By serving as a laboratory in Southeast Asia, in addition to its ability to manage regulatory approvals, PATHNOVA will play a role in the expansion of Todos Medical, while in combination we provide life-saving diagnostic evidence.”
For EPI requests, send an email to [email protected].
About Pathnova Laboratories Pte Ltd.
PATHNOVA is a Singapore-based start-up from the Temasek Life Science Laboratory in 2017. PATHNOVA focuses on the evolutionary detection of nasopharyne cancer (NPC) and autoimmune diseases through an AI framework created by Emeritus Professor Chan Soh Ha, who initiated the use of immunofluorescence (IFA) in the 1970s as a reference point for NPC detection.
NPC is a scourge affecting southern China and Southeast Asia. Driven by the Epstein-Barr virus, this cancer progresses faster than other cancers. Delaying the crushed onion for several months can mean the difference between a highly treatable tumor and a deadly tumor. Unlike maximum cancers that tend to occur at older ages (up to age 65), the maximum population at risk of apN is men over the age of forty-five to 50, when their contributions to the family circle and society are important. Although this disease can be stumbled upon by wonderful accuracy using the IFA test, maximum patients still stumble into the late stages (3 and 4), when survival is relatively worse. One of the main reasons is that the IFA is not scalable and requires tedious evaluation through highly qualified pathology personnel. PATHNOVA aims to solve this challenge by automating IFA by using the popularity of form to simultaneously trip and quantify the disease burden of NPCs for transparent instances. Boundary instances will be evaluated through a human pathology expert.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos, via its wholly-owned subsidiary Corona Diagnostics LLC, has formed strategic partnerships with Meridian Health, Moto-Para Foundation, Emerald Organic Products, Inc.’s subsidiaries Carie.com and Bonsa Health to help deploy COVID-19 testing in the United States.
For more information, please visit https://www.todosmedical.com/.
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Investor and Corporate Contact:Kim Sutton GolodetzLHA Investor RelationsSenior Vice President(212) [email protected]
Corporate Contact:Daniel HirschTodos Medical(347) [email protected]